TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28719554

Group type: EXPERIMENTAL
Intervention: Nonsurgical treatment with a figure‐of‐eight harness
Number of subjects: 117

Group type: COMPARATOR
Intervention: Surgical treatment with anteroinferior plate osteosynthesis
Number of subjects: 117
Study: 25492411

Group type: EXPERIMENTAL
Intervention: 150 µg corifollitropin alfa
Number of subjects: 79

Group type: COMPARATOR
Intervention: 450 IU follitropin beta
Number of subjects: 79
Study: 23970136

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention (multidisciplinary care, lifestyle program, aerobic and resistance exercise training for 12 months)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 83
Study: 22137076

Group type: EXPERIMENTAL
Intervention: Atorvastatin (80 mg before PCI and for 5 days after PCI)
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control (10 mg daily after PCI)
Number of subjects: 173

Group type: EXPERIMENTAL
Intervention: Atorvastatin group
Number of subjects: 173

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 173
Study: 18990504

Group type: EXPERIMENTAL
Intervention: AS+RT plus four cycles of TEE (paclitaxel, estramustine, etoposide)
Number of subjects: 397

Group type: COMPARATOR
Intervention: AS+RT
Number of subjects: 397
Study: 17257455

Group type: EXPERIMENTAL
Intervention: 1000 mg of paracetamol combined with 60 mg of pseudoephedrine
Number of subjects: 305
Study: 12734763

Group type: EXPERIMENTAL
Intervention: Trimipramine (300-400 mg)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Perazine (450-600 mg)
Number of subjects: 95
Study: 12736396

Group type: EXPERIMENTAL
Intervention: Montelukast (5 mg orally, once daily)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 25
Study: 10733466

Group type: EXPERIMENTAL
Intervention: Variant allele Thr198
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Variant allele Val379
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant PAFAH enzymes (Val379)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Recombinant PAFAH enzymes (Thr198)
Number of subjects: 0
Study: 8672190

Group type: EXPERIMENTAL
Intervention: Vibroacoustic stimulation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sham test
Number of subjects: 0
Study: 1478201

Group type: EXPERIMENTAL
Intervention: Lamotrigine (LTG) therapy for 12 weeks
Number of subjects: 28

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Chronic LTG therapy
Number of subjects: 28
Study: 6233622

Group type: EXPERIMENTAL
Intervention: zimelidine, a serotonin re‐uptake inhibitor
Number of subjects: 6

Group type: COMPARATOR
Intervention: imipramine, a noradrenaline re‐uptake inhibitor
Number of subjects: 6
Study: 2960361

Group type: EXPERIMENTAL
Intervention: 99Tcm-methylene diphosphonate (MDP)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 99Tcm-dicarboxypropane diphosphonate (DPD)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Visual analysis of MDP and DPD
Number of subjects: 12

Group type: COMPARATOR
Intervention: Visual and quantitative comparison in breast, prostatic, and lung carcinoma
Number of subjects: 12
Study: 31884206

Group type: EXPERIMENTAL
Intervention: Doxofylline 400 mg t.i.d. for one year
Number of subjects: 309
Study: 31079509

Group type: EXPERIMENTAL
Intervention: P2X7R rs2230911
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: P2X7R rs3751143
Number of subjects: 517

Group type: EXPERIMENTAL
Intervention: Estimated haplotype (rs1718119G-rs2230911C-rs3751143A)
Number of subjects: 517

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 517
Study: 27909071

Group type: EXPERIMENTAL
Intervention: Task-specific intervention for upper limb (UL) performance, 8 weeks duration
Number of subjects: 78
Study: 25950434

Group type: EXPERIMENTAL
Intervention: PEG + Asc
Number of subjects: 394

Group type: COMPARATOR
Intervention: NaPic/MgCit
Number of subjects: 394
Study: 23735472

Group type: COMPARATOR
Intervention: Transradial approach (reference intervention)
Number of subjects: 902

Group type: EXPERIMENTAL
Intervention: Transulnar approach (experimental intervention)
Number of subjects: 902
Study: 21255988

Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (not specified dosage or duration)
Number of subjects: 240
Study: 19221978

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg AM
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vildagliptin 100 mg PM
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Combined vildagliptin group
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Vildagliptin AM
Number of subjects: 100
Study: 16213468

Group type: EXPERIMENTAL
Intervention: Mild stressor
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 94
Study: 15569362

Group type: COMPARATOR
Intervention: Pantoprazole 40 mg b.i.d. (group A)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg b.i.d. plus mosapride 5 mg t.d.s. (group B)
Number of subjects: 61
Study: 11772293

Group type: EXPERIMENTAL
Intervention: Exisulind
Number of subjects: 0
Study: 10174521

Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environmental changes in parent organizations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thematic analysis of CQI implementation factors
Number of subjects: 0
Study: 7954528

Group type: EXPERIMENTAL
Intervention: Natural IFN beta
Number of subjects: 28

Group type: COMPARATOR
Intervention: Recombinant IFN beta
Number of subjects: 28

Group type: EXPERIMENTAL
Intervention: Natural IFN beta and Recombinant IFN beta
Number of subjects: 28
Study: 2885190

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at 50 micrograms kg‐1 hr‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion at 100 micrograms kg‐1 hr‐1
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Alfentanil infusion continued for two hours post-operatively at 20 micrograms kg‐1 hr‐1
Number of subjects: 14
Study: 31563355

Group type: EXPERIMENTAL
Intervention: High-Intensity Intermittent Calisthenic Training (HIICT)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Moderate Intensity Continuous Exercise (MICT)
Number of subjects: 25
Study: 28639947

Group type: EXPERIMENTAL
Intervention: Saah ECG
Number of subjects: 100

Group type: COMPARATOR
Intervention: conventional 12-lead ECG
Number of subjects: 100
Study: 26364041

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 10 mg i.v.
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Dexketoprofen 50 mg i.v.
Number of subjects: 24
Study: 23527363

Group type: EXPERIMENTAL
Intervention: Lateral sinus elevation with replacement of bone window and without bone graft (BW)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lateral sinus elevation and covering osteotomy site with a collagen membrane and without bone graft (CM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Lateral sinus elevation with autogenous bone graft (ABG)
Number of subjects: 24
Study: 21939612

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 112

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 112

Group type: COMPARATOR
Intervention: Olanzapine or Risperidone
Number of subjects: 112
Study: 18373607

Group type: EXPERIMENTAL
Intervention: CT image integration into the EnSite NavX mapping system with EnSite Fusion Dynamic Registration software module
Number of subjects: 23
Study: 16595247

Group type: EXPERIMENTAL
Intervention: 250 microg of recombinant hCG
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 500 microg of recombinant hCG
Number of subjects: 60
Study: 12900814

Group type: EXPERIMENTAL
Intervention: Triple-lumen catheter (TLC)
Number of subjects: 485

Group type: COMPARATOR
Intervention: Dual-lumen catheter (DLC)
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Femoral sites
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Jugular sites
Number of subjects: 485

Group type: EXPERIMENTAL
Intervention: Combined jugular and subclavian sites
Number of subjects: 485
Study: 11296717

Group type: EXPERIMENTAL
Intervention: Placement learning (observing the virtual environment from a fixed position)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational learning (observing an experimenter search the virtual environment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Various training procedures in the C‐G Arena
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Observational learning procedure
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: C‐G Arena procedures
Number of subjects: 0
Study: 9241299

Group type: EXPERIMENTAL
Intervention: Nifedipine orally (n = 95)
Number of subjects: 185

Group type: COMPARATOR
Intervention: Ritodrine intravenously (n = 90)
Number of subjects: 185
Study: 8287862

Group type: EXPERIMENTAL
Intervention: Chloroquine (25mg/kg over three days)
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Sulfadoxine-pyrimethamine (single curative dose)
Number of subjects: 47
Study: 3539557

Group type: COMPARATOR
Intervention: Conventional rubber band ligation
Number of subjects: 205

Group type: EXPERIMENTAL
Intervention: Triple rubber band ligation
Number of subjects: 205
Study: 31350236

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide (Acli-BID) administered twice daily for 8 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tiotropium bromide hydrate (Tio-QD) administered once daily for 8 weeks
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Aclidinium bromide (Acli-BID)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Tiotropium bromide hydrate (Tio-QD)
Number of subjects: 44
Study: 27543047

Group type: EXPERIMENTAL
Intervention: 1-RM bench press strength
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Average isometric handgrip strength of both hands
Number of subjects: 295

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 295
Study: 25886467

Group type: COMPARATOR
Intervention: Multi-component intervention to improve availability and promotion of fruit and vegetable products and non sugar-sweetened drinks in sporting club canteens.
Number of subjects: 1143

Group type: COMPARATOR
Intervention: Control group (not specified in detail).
Number of subjects: 1143
Study: 24142633

Group type: EXPERIMENTAL
Intervention: 15 mg of pioglitazone daily
Number of subjects: 121

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study: 21696244

Group type: EXPERIMENTAL
Intervention: TRAIN (Transit to Russia AIDS Intervention with Newcomers)
Number of subjects: 60
Study: 19609187

Group type: EXPERIMENTAL
Intervention: Workbook-based, project-focused curriculum
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned)
Number of subjects: 31
Study: 16415686

Group type: EXPERIMENTAL
Intervention: Bausch & Lomb ReNu MultiPlus
Number of subjects: 21

Group type: COMPARATOR
Intervention: Alcon No Rub Opti‐Free Express
Number of subjects: 21

Group type: COMPARATOR
Intervention: Advanced Medical Optics Complete Moisture Plus
Number of subjects: 21
Study: 15307518

Group type: EXPERIMENTAL
Intervention: Specific immunotherapy with Allergovit or Novo Helisen Depot for 3 years
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (pharmacologically treated allergic rhinitis)
Number of subjects: 112
Study: 12027048

Group type: EXPERIMENTAL
Intervention: Neuroleptic medications
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 9052591

Group type: EXPERIMENTAL
Intervention: Misoprostol (100 micrograms, intravaginally every 4 hours)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Oxytocin (intravenous)
Number of subjects: 130
Study: 8342578

Group type: EXPERIMENTAL
Intervention: Intranasal dDAVP (20-40 micrograms according to body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Intravenous dDAVP (2-4 micrograms according to body weight)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Comparison of Uosm between intranasal and intravenous dDAVP at T4
Number of subjects: 18
Study: 3525168

Group type: EXPERIMENTAL
Intervention: Oral anticoagulants (acenocoumarin 1-6 mg daily regulated to keep prothrombin time within the range of 25 to 35%)
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-treated control patients
Number of subjects: 38
Study: 29720374

Group type: EXPERIMENTAL
Intervention: Education plus exercise (EDX; n=69)
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Corticosteroid injection (CSI; n=66)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Wait and see approach (WS; n=69)
Number of subjects: 204
Study: 24699555

Group type: EXPERIMENTAL
Intervention: Normocaloric group (100% of daily energy expenditure)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hypocaloric group (50% of daily energy expenditure)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Normocaloric group
Number of subjects: 100

Group type: COMPARATOR
Intervention: Hypocaloric group
Number of subjects: 100
Study: 24674654

Group type: EXPERIMENTAL
Intervention: Monthly chemoprophylaxis with sulphadoxine‐pyrimethamine plus artesunate
Number of subjects: 349

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 349
Study: 22525705

Group type: EXPERIMENTAL
Intervention: 12‐week computer‐based memory‐attention training program based on recognition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitively stimulating activities (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Follow-up test session 6 months after training
Number of subjects: 0
Study: 20216560

Group type: EXPERIMENTAL
Intervention: B(2) - 2 microg vitamin B12
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: B(10) - 10 microg vitamin B12
Number of subjects: 300

Group type: COMPARATOR
Intervention: B(0) - placebo (0 microg vitamin B12)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: F(200) - 200 microg folic acid
Number of subjects: 300

Group type: COMPARATOR
Intervention: F(0) - placebo (0 microg folic acid)
Number of subjects: 300
Study: 17852143

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg (CEE, n=24)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens + medroxyprogesterone acetate 5 mg (CEE/MPA, n=34)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: 17beta‐estradiol 1 mg + norethisterone acetate 0.5 mg (E2/NETA, n=66)
Number of subjects: 216

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n=24)
Number of subjects: 216

Group type: COMPARATOR
Intervention: No therapy (control, n=68)
Number of subjects: 216
Study: 16221243

Group type: EXPERIMENTAL
Intervention: Intraperitoneal cefazolin plus netilmicin
Number of subjects: 102

Group type: COMPARATOR
Intervention: Intraperitoneal cefazolin plus ceftazidime
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Both treatment regimens
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with RRF
Number of subjects: 102
Study: 12145035

Group type: EXPERIMENTAL
Intervention: Large-Dose Aprotinin (4 M KIU bolus before surgery followed by a continuous infusion of 1 M KIU/h until the end of surgery)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Large-Dose Aprotinin
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Small-Dose Aprotinin (2 M KIU bolus plus 0.5 M KIU/h)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 10413563

Group type: COMPARATOR
Intervention: 2-week treatment with trihexyphenidyl
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acute subclinical dose of scopolamine
Number of subjects: 0
Study: 7472817

Group type: EXPERIMENTAL
Intervention: Penicillin V potassium, 250 mg, twice daily
Number of subjects: 400

Group type: COMPARATOR
Intervention: Placebo tablet, twice daily
Number of subjects: 400
Study: 1644458

Group type: EXPERIMENTAL
Intervention: Pneumatic plantar impulse device
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 23
Study: 6098051

Group type: EXPERIMENTAL
Intervention: icosapentaenoic acid (20:5n‐3) 150 mg/day for one month
Number of subjects: 0

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 0
Study: 31493178

Group type: EXPERIMENTAL
Intervention: Cetuximab/FOLFIRI
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Systemic tetracyclines
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Geriatric evaluation
Number of subjects: 0
Study: 29400671

Group type: EXPERIMENTAL
Intervention: mCIMT combined with TR
Number of subjects: 24

Group type: COMPARATOR
Intervention: mCIMT alone
Number of subjects: 24
Study: 25060803

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid (clobetasol propionate) before and just after PDT
Number of subjects: 22

Group type: COMPARATOR
Intervention: Conventional PDT
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Topical corticosteroid
Number of subjects: 22
Study: 22672287

Group type: EXPERIMENTAL
Intervention: Interactive video dance game
Number of subjects: 168

Group type: COMPARATOR
Intervention: Brisk walking
Number of subjects: 168

Group type: COMPARATOR
Intervention: Delayed entry controls
Number of subjects: 168
Study: 19209075

Group type: EXPERIMENTAL
Intervention: Heavy-load resistance exercises (3 sets of 4 repetitions at 90% of 1RM)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Heavy-load resistance plus stretching exercises (3 sets of 4 repetitions at 90% of 1RM and 3 stretching exercises for 15 seconds each)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Static stretching exercises (3 stretching exercises for 15 seconds each)
Number of subjects: 24
Study: 17596812

Group type: EXPERIMENTAL
Intervention: Azithromycin
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Beta-lactam
Number of subjects: 83
Study: 15505487

Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d
Number of subjects: 194

Group type: COMPARATOR
Intervention: Chlorthalidone (C) 25 mg/d
Number of subjects: 194

Group type: EXPERIMENTAL
Intervention: Losartan (L) 50 mg/d after washout from C
Number of subjects: 194
Study: 11906584

Group type: COMPARATOR
Intervention: Probiotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Prebiotics
Number of subjects: 0
Study: 9770962

Group type: EXPERIMENTAL
Intervention: Prospidin (500 mg for 5 days in hospital, 500-1000 mg for a month as maintenance)
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Methotrexate (30 mg a week i.v. in hospital, 7-10 mg a week as maintenance)
Number of subjects: 93
Study: 7932282

Group type: EXPERIMENTAL
Intervention: Cholinergic REM induction test (CRIT) with 1.5 mg RS 86 (muscarinic agonist)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Cholinergic stimulation
Number of subjects: 119
Study: 3282826

Group type: EXPERIMENTAL
Intervention: 2,000 microgram per day dose of beclomethasone dipropionate aerosol (BDP)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 800 micrograms per day of standard BDP
Number of subjects: 0
Study: 31273505

Group type: EXPERIMENTAL
Intervention: Occupational therapy (OT) intervention with healthy lifestyle education handbook, provided at discharge and at 1-month and 3-month follow-up
Number of subjects: 68

Group type: COMPARATOR
Intervention: Non-intervention group receiving the same CRC education handbook only at discharge preparation
Number of subjects: 68
Study: 29357331

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy with 8 pulses per second (medium‐dose)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy with one pulse per second (low‐dose)
Number of subjects: 231

Group type: COMPARATOR
Intervention: Continuous mode fluoroscopy (high‐dose)
Number of subjects: 231

Group type: EXPERIMENTAL
Intervention: Pulsed fluoroscopy (both medium and low doses)
Number of subjects: 231
Study: 27225977

Group type: EXPERIMENTAL
Intervention: Cyclic NMES
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: EMG-triggered NMES
Number of subjects: 122

Group type: EXPERIMENTAL
Intervention: Sensory stimulation
Number of subjects: 122
Study: 25135244

Group type: EXPERIMENTAL
Intervention: 40 mg/mL gentamicin solution (four intratympanic injections, administered weekly)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Two injections of gentamicin solution and two injections of placebo (in random order)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Placebo (four injections)
Number of subjects: 3
Study: 23052572

Group type: EXPERIMENTAL
Intervention: Behavioral support for smoking cessation
Number of subjects: 452
Study: 20160654

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.05 mg/kg per day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.2 mg/kg per day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil 0.4 mg/kg per day
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil
Number of subjects: 93

Group type: EXPERIMENTAL
Intervention: Candesartan cilexetil in participants with proteinuric renal disease
Number of subjects: 93
Study: 19027898

Group type: EXPERIMENTAL
Intervention: rhBMP-7
Number of subjects: 120

Group type: COMPARATOR
Intervention: PRP
Number of subjects: 120
Study: 16877729

Group type: EXPERIMENTAL
Intervention: Weekly docetaxel
Number of subjects: 56

Group type: COMPARATOR
Intervention: Docetaxel every 3 weeks
Number of subjects: 56
Study: 14610417

Group type: EXPERIMENTAL
Intervention: Oral transmucosal fentanyl citrate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral morphine
Number of subjects: 0
Study: 10781769

Group type: EXPERIMENTAL
Intervention: Crosswire guidewire strategy
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional guidewire strategy
Number of subjects: 0
Study: 9119091

Group type: EXPERIMENTAL
Intervention: Early induction of labour with oxytocin at a rate of 2.5 mU/min
Number of subjects: 154

Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 154

Group type: EXPERIMENTAL
Intervention: Early induction of labour with oxytocin
Number of subjects: 154
Study: 1729430

Group type: EXPERIMENTAL
Intervention: Relaxation Technique (RT)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (no RT)
Number of subjects: 40
Study: 6729454

Group type: EXPERIMENTAL
Intervention: Triazolam
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Flurazepam
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30807405

Group type: EXPERIMENTAL
Intervention: Restorelle Y mesh
Number of subjects: 62

Group type: COMPARATOR
Intervention: Flat mesh
Number of subjects: 62
Study: 29620692

Group type: EXPERIMENTAL
Intervention: Agomelatine 25-50 mg/d
Number of subjects: 264

Group type: COMPARATOR
Intervention: Paroxetine 20-40 mg/d
Number of subjects: 264